Date: 2012-04-12
Type of information: Fundraising
Company: Aleva Neurotherapeutics (Switzerland)
Investors: Banexi Ventures Partners
Amount: CHF 4 million (€3.22 million)
Funding type: series B financing round
Planned used: The proceeds will be used to advance Aleva’s leading-edge neurostimulation products through clinical development up to CE marking. Aleva´s products are based on its proprietary, next-generation microDBS™ technology for Deep Brain Stimulation therapy (DBS).
Others: Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, has announced the closing of a Series B financing round totaling CHF 4.0 million.
Therapeutic area: Neurodegenerative diseases - CNS diseases
